FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Reissmann

Research Profile

Chemicals & Drugs

Procedures

Physiology

Pregnancy

Disorders

Living Beings

Co-author Network

Publications

TOP 3
Jörg Engel; Ricardo Felberbaum; Klaus Junge; Thomas Reissmann; Klaus Diedrich
Inhibin B on the day of HCG-administration is a predictive factor for failure in assisted reproduction cycles.
Klaus Diedrich; R Frydman; Paul Devroey; Ricardo Felberbaum; Andrew V Schally; Thomas Reissmann; J Engel
Comment on the debate article: embryo implantation: the Rubicon for GnRH antagonists.
Nikos Nikolettos; Safaa Al-Hasani; Ricardo Felberbaum; L Cem Demirel; H Riethmüller-Winzen; Thomas Reissmann; Beate Schöpper; Rita Sturm; Klaus Diedrich
Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, cetrorelix, and GnRH agonists.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Reissmann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2003: Jörg Engel; Ricardo Felberbaum; Klaus Junge; Thomas Reissmann; Klaus Diedrich
Inhibin B on the day of HCG-administration is a predictive factor for failure in assisted reproduction cycles.
Archives of gynecology and obstetrics 2003;268(4):278-80.
2001: Klaus Diedrich; R Frydman; Paul Devroey; Ricardo Felberbaum; Andrew V Schally; Thomas Reissmann; J Engel
Comment on the debate article: embryo implantation: the Rubicon for GnRH antagonists.
Human reproduction (Oxford, England) 2001;16(6):1305-6.
2000: Nikos Nikolettos; Safaa Al-Hasani; Ricardo Felberbaum; L Cem Demirel; H Riethmüller-Winzen; Thomas Reissmann; Beate Schöpper; Rita Sturm; Klaus Diedrich
Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, cetrorelix, and GnRH agonists.
European journal of obstetrics, gynecology, and reproductive biology 2000;93(1):91-5.
1998: Carola Albano; G Grimbizis; Johan Smitz; H Riethmüller-Winzen; Thomas Reissmann; André Van Steirteghem; Paul Devroey
The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix.
Fertility and sterility 1998;70(2):357-9.
1998: Ricardo Felberbaum; Ute Germer; Michael Ludwig; H Riethmüller-Winzen; S Heise; I Buttge; Otmar Bauer; Thomas Reissmann; J Engel; Klaus Diedrich
Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
Human reproduction (Oxford, England) 1998;13(6):1660-8.
1997: D Gonzalez-Barcena; R B Alvarez; E P Ochoa; I C Cornejo; A M Comaru-Schally; Andrew V Schally; J Engel; Thomas Reissmann; H Riethmüller-Winzen
Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix.
Human reproduction (Oxford, England) 1997;12(9):2028-35.
1996: Thomas Reissmann; T Klenner; W Deger; Philip Hilgard; G P McGregor; K Voigt; J Engel
Pharmacological studies with cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1574-9.
1996: Ricardo Felberbaum; Thomas Reissmann; Wolfgang Küpker; Safaa Al-Hasani; Otmar Bauer; T Schill; C Zoll; C Diedrich; Klaus Diedrich
Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages.
Journal of assisted reproduction and genetics 1996;13(3):216-22.
1995: Thomas Reissmann; Ricardo Felberbaum; Klaus Diedrich; J Engel; A M Comaru-Schally; Andrew V Schally
Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview.
Human reproduction (Oxford, England) 1995;10(8):1974-81.
1995: Ricardo Felberbaum; Thomas Reissmann; Wolfgang Küpker; Otmar Bauer; Safaa Al-Hasani; C Diedrich; Klaus Diedrich
Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility.
European journal of obstetrics, gynecology, and reproductive biology 1995;61(2):151-5.
1995: Jacek Pinski; Andrew V Schally; T Yano; Kate Groot; G Srkalovic; P Serfozo; Thomas Reissmann; M Bernd; W Deger; B Kutscher
Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).
International journal of peptide and protein research 1995;45(5):410-7.
1995: Ricardo Felberbaum; Thomas Reissmann; C Zoll; Wolfgang Küpker; Safaa Al-Hasani; C Diedrich; Klaus Diedrich
[GnRH antagonists in gynecology: initial results within the scope of controlled ovarian hyperstimulation].
Gynäkologisch-geburtshilfliche Rundschau 1995;35 Suppl 1():113-7.
1994: Klaus Diedrich; C Diedrich; E Santos; C Zoll; Safaa Al-Hasani; Thomas Reissmann; Dieter Krebs; D Klingmüller
Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.
Human reproduction (Oxford, England) 1994;9(5):788-91.
1994: Thomas Reissmann; Klaus Diedrich; A M Comaru-Schally; Andrew V Schally
Introduction of LHRH-antagonists into the treatment of gynaecological disorders.
Human reproduction (Oxford, England) 1994;9(5):769.
1994: Klaus Diedrich; C Diedrich; E Santos; Otmar Bauer; C Zoll; Safaa Al-Hasani; Thomas Reissmann; Dieter Krebs; D Klingmüller
[Suppression of endogenous LH increase in ovarian stimulation with the GnRH antagonist Cetrorelix].
Geburtshilfe und Frauenheilkunde 1994;54(4):237-40.
1992: Thomas Reissmann; Philip Hilgard; J H Harleman; J Engel; A M Comaru-Schally; Andrew V Schally
Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
Journal of cancer research and clinical oncology 1992;118(1):44-9.
1991: Philip Hilgard; E Kampherm; L Nolan; J Pohl; Thomas Reissmann
Investigation into the immunological effects of miltefosine, a new anticancer agent under development.
Journal of cancer research and clinical oncology 1991;117(5):403-8.
1989: Thomas Reissmann; Rainer Voegeli; J Pohl; Philip Hilgard
Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.
Cancer immunology, immunotherapy : CII 1989;28(3):179-84.
1989: Thomas Reissmann; Philip Hilgard; Rainer Voegeli; J Zeller
Evidence of a role for NK cells in oxazaphosphorine-mediated tumor regression.
Journal of cancer research and clinical oncology 1989;115(6):525-30.
1987: J Pohl; Thomas Reissmann; Rainer Voegeli
Oxazaphosphorine effects in L 5222 rat leukemia.
Methods and findings in experimental and clinical pharmacology 1987;9(9):589-94.